What interviewers actually evaluate

Regeneron Pharmaceuticals sales interviews test whether candidates understand how to sell biologic medicines in specialty therapy areas where clinical complexity, payer access barriers, and patient support program coordination define the selling environment – and where Regeneron's portfolio of DUPIXENT, EYLEA, LIBTAYO, and PRALUENT requires deep disease state and mechanism of action knowledge that differentiates biologic selling from primary care pharmaceutical selling. Sales at Regeneron spans DUPIXENT specialty selling (where dupilumab's approvals across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and food allergies in adults and pediatric populations require sales representatives to develop clinical fluency across multiple specialties – dermatologists, allergists, and pulmonologists for the inflammatory disease indications – and where patient identification depends on helping physicians recognize the type 2 inflammatory phenotype characterized by elevated IgE, blood eosinophilia, and fractional exhaled nitric oxide that predicts which moderate-to-severe patients will benefit most from IL-4/IL-13 pathway blockade), EYLEA access and account management in ophthalmology (where aflibercept for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion is sold primarily to retina specialist practices that administer it as a buy-and-bill injectable – meaning the practice purchases the drug inventory and bills payers after administration, creating account management relationships where formulary coverage, reimbursement coding, and office inventory management are key selling dimensions alongside clinical efficacy), LIBTAYO oncology selling in collaboration with Sanofi (where cemiplimab's approvals in cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer and cervical cancer require engagement with oncologists and dermatologists who treat patients with few prior treatment options, and where Regeneron and Sanofi co-promote LIBTAYO with coordinated field forces that must align messaging and call strategy across both companies' representatives), and payer access and reimbursement navigation (where biologic medicines priced at tens of thousands of dollars annually require prior authorization for most insurance plans, and where specialty pharmacy coordination, step therapy requirements that mandate prior failure on less expensive therapies, and patient out-of-pocket cost assistance programs managed by Regeneron Cares affect which appropriate patients can actually access the medicines their physicians prescribe). Interviewers evaluate whether candidates understand biologic patient identification and clinical selling, ophthalmology buy-and-bill account management, oncology access dynamics, and payer barrier navigation for high-cost specialty medicines.

Start your free Regeneron Pharmaceuticals Sales practice session.

What interviewers actually evaluate

Biologic Patient Identification, Buy-and-Bill Account Management, and Payer Access Navigation

Regeneron sales interviews probe whether candidates understand how selling specialty biologics differs from selling primary care or oral specialty medicines in the clinical complexity of patient identification (DUPIXENT's eligibility is not simply defined by diagnosis – a patient with atopic dermatitis who has not tried adequate topical therapy is not an appropriate DUPIXENT candidate, while a patient with moderate-to-severe atopic dermatitis with inadequate control on topical steroids and documented type 2 inflammatory biomarkers is the ideal candidate whose prescribing physician needs to understand the clinical profile in depth, requiring sales representatives to have enough clinical knowledge to help physicians distinguish appropriate from inappropriate patients rather than simply promoting a brand claim), the buy-and-bill economic complexity for EYLEA (retina specialist practices that buy EYLEA inventory and administer it to patients in-office are making an investment in drug inventory that creates cash flow risk if claims are denied, reimbursement rates change, or the practice administration makes coding errors – EYLEA sales work in retina involves educating office staff on correct J-code billing, helping practices optimize their reimbursement workflow, and managing the practice relationship during coverage gaps or reimbursement disputes that affect whether the practice continues to purchase inventory), and the co-promotion coordination complexity with Sanofi (DUPIXENT and LIBTAYO are co-promoted with Sanofi field forces that have their own call targets, messaging guidance, and incentive structures, creating the unusual selling environment where Regeneron representatives must coordinate with a partner company's representatives on account-level strategy while maintaining consistent clinical messaging – and where customer-facing interactions require clarity about which company's representative is calling and what each is authorized to discuss).

The biosimilar competition dimension for EYLEA adds a current market access challenge: biosimilar aflibercept products have entered the US market and are priced below EYLEA, creating formulary pressure from PBMs and payers who offer biosimilar substitution or preferential coverage to reduce their specialty drug spend – EYLEA sales representatives must communicate the clinical differentiation of EYLEA HD (the high-dose 8mg formulation approved in 2023 with extended dosing intervals) and the EYLEA brand's established safety and efficacy record against these access pressures.

What gets scored in every session

Specific, sentence-level feedback.

Dimension	What it measures	How to answer
DUPIXENT biologic patient identification and clinical selling	Do you understand how to help prescribers identify appropriate DUPIXENT candidates – the type 2 inflammatory biomarker profile, the step therapy requirements that must be documented, and how to communicate the mechanism of IL-4/IL-13 pathway blockade in terms that connect to the disease pathophysiology physicians recognize? We flag sales answers that treat DUPIXENT selling as brand awareness without engaging with the patient selection clinical content.	Type 2 inflammation biomarker identification, step therapy documentation, IL-4/IL-13 mechanism communication
EYLEA buy-and-bill account management	Can you describe how to manage EYLEA accounts in retina specialist practices – what the buy-and-bill purchasing model means for practice cash flow, how to support correct J-code billing and reimbursement workflow, and how to maintain account relationships during biosimilar entry and payer formulary pressure? We score whether your EYLEA account management approach engages with the financial and administrative dimensions of the buy-and-bill model.	J-code billing support, buy-and-bill inventory management, biosimilar formulary pressure response
Payer access and prior authorization navigation	Do you understand how to navigate payer barriers for high-cost biologics – how prior authorization criteria are set, what step therapy documentation is required to support PA approvals, and how to coordinate with specialty pharmacy and Regeneron Cares patient assistance to ensure that approved patients can access prescribed medicines? We detect sales answers that treat access as an administrative function rather than a core selling skill for biologic medicines.	PA criteria navigation, specialty pharmacy coordination, patient assistance program utilization
Co-promotion coordination with Sanofi	Can you describe how DUPIXENT and LIBTAYO co-promotion with Sanofi works in practice – how Regeneron and Sanofi coordinate call strategy and messaging at specific accounts, what each company's representatives are authorized to discuss, and how to handle account situations where the two companies' commercial priorities may not be fully aligned? We flag sales answers that describe co-promotion as simple territory division rather than an ongoing coordination challenge at the account level.	Account-level co-promotion coordination, messaging alignment, partner prioritization management

How a session works

Step 1: Choose a Regeneron Pharmaceuticals sales scenario – DUPIXENT patient identification and biologic selling across dermatology, allergy, and pulmonology, EYLEA buy-and-bill account management in retina, LIBTAYO oncology access and co-promotion with Sanofi, or payer prior authorization and patient access program navigation.

Step 2: The AI interviewer asks realistic Regeneron-style questions: how you would approach a dermatologist who currently prescribes DUPIXENT primarily for her most severe patients with documented biologic-level disease but who has 30 additional patients on inadequately controlled topical steroids who fit the DUPIXENT clinical profile – and what clinical and access tools you would bring to the appointment to help her identify and initiate those patients, how you would manage the relationship with a high-volume retina practice that has shifted 40 percent of its wet AMD patients from EYLEA to a biosimilar aflibercept after their PBM updated formulary coverage and created a prior authorization requirement for EYLEA that the practice finds administratively burdensome, or how you would coordinate with the Sanofi LIBTAYO representative who covers the same oncology accounts to develop a joint call strategy for a large oncology group practice where both of you are competing for call access time with the same five oncologists.

Step 3: You respond as you would in the actual interview. The system scores your answer on biologic patient identification, EYLEA account management, payer access navigation, and Sanofi co-promotion coordination.

Step 4: You get sentence-level feedback on what demonstrated genuine specialty biologic selling expertise and what needs stronger patient identification clinical content or access barrier navigation specificity.

Frequently Asked Questions

How does patient identification work for DUPIXENT in atopic dermatitis?
DUPIXENT is approved for patients 6 months of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies or when those therapies are not advisable. The clinical identification of appropriate patients involves recognizing the severity of disease using tools like EASI (Eczema Area and Severity Index) scores, confirming inadequate control with appropriate topical therapy, and identifying the type 2 inflammatory phenotype that predicts strong response – patients with elevated serum IgE levels, blood eosinophilia, or high fractional exhaled nitric oxide tend to have the Th2-driven inflammation that IL-4/IL-13 pathway blockade addresses. Payer prior authorization requirements typically codify these clinical criteria in their PA forms, so sales representatives who help dermatologists and allergists document the clinical basis for DUPIXENT prescriptions in a way that satisfies PA requirements improve the probability that prescriptions move through the access pathway and result in patient starts rather than PA denials that discourage prescribers.

What makes the EYLEA buy-and-bill model distinctive in ophthalmology sales?
EYLEA is administered by retina specialists as an intravitreal injection delivered in an office procedure – the physician injects aflibercept directly into the vitreous of the eye to reduce the neovascularization driving vision loss in wet AMD, DME, and retinal vein occlusion. In the buy-and-bill model, the retina practice purchases EYLEA at the wholesale acquisition cost, administers it to the patient, then bills the patient's Medicare Part B or commercial insurance for both the drug and the administration – recognizing reimbursement based on the applicable J-code (J0178 for aflibercept) at a rate set by CMS or commercial payer negotiation. The practice earns the difference between what it pays for EYLEA and what it receives in reimbursement – the "buy and bill spread" – which means that reimbursement rate changes or payer formulary decisions that require prior authorization for EYLEA affect the practice's economic relationship with the drug as well as the clinical workflow.

How does the Regeneron-Sanofi co-promotion relationship work in the field?
Regeneron and Sanofi share commercialization responsibilities for DUPIXENT and LIBTAYO under collaboration agreements that provide Regeneron a portion of US profits while Sanofi handles the majority of international commercialization. In the US, both Regeneron and Sanofi deploy field sales representatives who call on the same physician targets – the DUPIXENT field force includes representatives employed by both companies who receive coordinated messaging guidance and are expected to align their call strategy through shared account planning tools. At the account level, the two companies' representatives divide call responsibilities based on their respective strengths – Regeneron representatives may focus on certain specialties or accounts while Sanofi representatives focus on others – but both companies' representatives are expected to advance the same approved messaging in their customer interactions. The coordination challenge arises when account dynamics create situations where the two companies' immediate commercial interests diverge: Regeneron may prioritize an account that Sanofi has deprioritized, or vice versa, requiring account-level dialogue between the co-promotion teams to align on strategy.

How does payer access for DUPIXENT work through specialty pharmacy?
DUPIXENT is dispensed through specialty pharmacies rather than retail pharmacy chains – the cold storage requirements, clinical monitoring expectations, and high cost of biologic therapy make specialty pharmacy distribution standard for DUPIXENT. After a physician writes a DUPIXENT prescription, it routes to a specialty pharmacy (typically through the physician's office or Regeneron's HUB services) where benefits verification confirms the patient's insurance coverage and prior authorization status. Specialty pharmacies conduct PA submission on behalf of prescribers who use the HUB service, track PA approval or denial, and manage appeal submission if needed. For patients without adequate insurance coverage or with high out-of-pocket exposure even after insurance, Regeneron Cares offers patient assistance programs and co-pay cards that reduce patient cost-sharing. Sales representatives who understand how to use Regeneron Cares and specialty pharmacy support tools, and who can walk prescribers' office staff through the HUB enrollment process, reduce the access barriers that prevent appropriate patients from starting therapy.

How is EYLEA HD differentiated from biosimilar aflibercept in the current market?
EYLEA HD – the higher-dose 8mg formulation of aflibercept approved by the FDA in August 2023 – was developed specifically to extend treatment intervals beyond what the standard 2mg dose typically achieves in clinical practice. In pivotal trials for wet AMD and DME, EYLEA HD 8mg demonstrated efficacy with dosing intervals of up to 16 weeks after the initial dosing phase for a substantial proportion of patients, potentially reducing the frequency of in-office injections compared to standard dosing. Biosimilar aflibercept products approved in 2024 replicate the 2mg formulation of EYLEA at lower list prices but do not have the 8mg formulation that EYLEA HD provides. For retina specialists whose patients would benefit from extended dosing intervals – particularly older patients for whom frequent in-office visits are burdensome – EYLEA HD offers a clinical option that biosimilar aflibercept cannot match, providing EYLEA a differentiation argument beyond brand familiarity as the biosimilar market develops.